Adipokines Emerge as Active Players in Inflammatory Bowel Disease Biology

Inflammatory bowel disease has long been framed as a disorder of the gut wall, but this review treats adipose tissue as a biologically active partner in the disease process. Across 74 studies published through April 2026, adipokines repeatedly surfaced as mediators tied to inflammation, nutritional status, disease activity, and treatment response in inflammatory bowel disease. The clinical appeal is straightforward: if circulating proteins released by fat tissue mirror inflammatory burden, they could help clinicians track a disease that often shifts between remission and flare with little warning.

One sentence captures the core signal: adipose tissue is not passive in IBD.

The review focuses on several molecules that have drawn the most attention in adult and pediatric cohorts, especially adiponectin, leptin, and resistin. These mediators sit at the intersection of metabolism and immunity, and that dual role makes them attractive candidates for translational work in chronic intestinal inflammation. In biologic terms, adipokines may influence cytokine signaling, immune-cell recruitment, and the balance between pro-inflammatory and anti-inflammatory pathways. In a disease defined by relapsing mucosal injury, even modest shifts in those signals could matter clinically.

Leptin Tracks Nutrition More Consistently Than It Tracks Inflammation

Among the adipokines reviewed, leptin was most often associated with nutritional status parameters rather than direct measures of inflammatory activity. That pattern fits its established physiology. Leptin reflects energy stores and communicates metabolic sufficiency to the brain and immune system, so its relationship to body composition, weight loss, and nutritional compromise in IBD is biologically plausible. In pediatric disease, where growth failure and impaired intake can complicate the clinical picture, a biomarker linked to nutrition may be as useful as one linked to inflammation.

Leptin’s relevance is not limited to body mass alone. Because immune cells express leptin receptors, the molecule may still participate in inflammatory signaling, even when its most visible clinical associations are nutritional. The review does not flatten that complexity into a single conclusion. Instead, it shows a recurring divide in the literature: some adipokines appear more useful for describing the patient’s metabolic state, while others appear more closely tied to disease activity itself.

Resistin and Visfatin Show the Most Promising Disease-Activity Signals

Two adipokines stood out for a different reason. resistin and visfatin were more frequently linked with disease activity and with responses to anti-inflammatory and nutritional interventions. In practical terms, those associations are more compelling for bedside use than a static biomarker profile, because a clinically useful marker should move when the disease moves. If a marker changes alongside mucosal inflammation or treatment response, it may eventually help identify patients who are improving, plateauing, or drifting toward relapse.

The biology fits the signal. Resistin is often discussed as a pro-inflammatory mediator, and visfatin has been linked to inflammatory pathways and immune activation. In a condition such as IBD, where tissue injury is sustained by dysfunctional immune signaling, molecules that reflect those pathways may capture active disease more accurately than markers that simply register nutritional depletion. The review’s emphasis on treatment-related change is especially important, since a biomarker that responds to intervention has greater potential to support therapeutic monitoring.

Why These Molecules Matter in a Chronic Relapsing Disorder

IBD does not unfold along a single inflammatory pathway, which is one reason conventional clinical assessment can lag behind biology. Patients may appear stable while subclinical inflammation persists, and symptoms may not always track mucosal injury with precision. Adipokines could help close that gap by offering a window into the combined metabolic and immune activity of the disease state. In that setting, a circulating adipokine profile could eventually complement fecal markers, endoscopic assessment, and standard laboratory testing rather than replace them.

The concept is attractive, but the evidence remains uneven. The review found substantial heterogeneity across studies, largely because methods differed and populations were not uniform. Some studies focused on adults, others on children; some emphasized active disease, others remission; some examined treatment effects, while others assessed baseline associations. Those differences make pooled interpretation difficult and help explain why the literature has not yet converged on a single adipokine strategy for routine practice.

Heterogeneity Limits Immediate Clinical Translation

The strongest message in this review is not that adipokines are ready for routine use, but that the field is biologically credible and still incomplete. Variability in study design, patient selection, and measurement approaches has blurred comparisons across cohorts. Without consistency in sampling, disease phenotyping, and timing relative to flare or therapy, even a promising biomarker can look unstable.

Still, the direction of the evidence is hard to ignore. Multiple adipokines appear to participate in the inflammatory network of IBD, and some of them may distinguish disease activity from nutritional status with better fidelity than others. Resistin and visfatin look especially interesting because their levels seem to shift with inflammation and treatment response, making them candidates for prognostic research. For clinicians, that raises a practical question: can adipokines eventually help identify who is truly responding to therapy, rather than who merely feels better?

The answer will depend on studies that are larger, better standardized, and designed to test whether adipokines add value beyond existing markers. Diagnostic usefulness, prognostic accuracy, and treatment-monitoring performance all remain open questions. For now, the review positions adipokines as a credible biologic layer in IBD rather than a finished clinical tool, with resistin and visfatin carrying the most translational promise because they appear to move with disease activity and therapeutic change.


Reporting by Dr. A. Nikhil Krishnan, MBBS for Medicine World Foundation, with additional data provided by Frontiers in Immunology.